Although rosacea flare-ups are a common aspect of rosacea, patients are able to successfully control them with medication and by avoiding factors that aggravate their condition, according to a recent survey by the National Rosacea Society.
In the survey of 2,083 rosacea patients on the nature of flare-ups -- the reappearance or increased intensity of symptoms -- 32 percent said they experienced flare-ups frequently, while 55 percent said they experienced them occasionally and 12 percent reported they rarely or never experience this problem.
For 55 percent, flare-ups usually last less than a week, and 15 percent said they last less than a day. However, 35 percent of the respondents reported their flare-ups usually last more than a week and 11 percent said more than a month.
Although 8 percent described their flare-ups as severe, 58 percent said their flare-ups are moderate and 30 percent said they are mild.
Fortunately, 90 percent of the survey respondents said medication had been effective or somewhat effective in controlling their rosacea flare-ups, and 78 percent said avoiding factors that aggravate their condition had been effective or somewhat effective. Of those who said both medication and avoidance of rosacea tripwires had been effective, only 12 percent reported that their flare-ups were frequent and only 4 percent described them as severe.
The National Rosacea Society is a 501(c)(3) nonprofit organization whose mission is to improve the lives of people with rosacea by raising awareness, providing public health information and supporting medical research on this widespread but little-known disorder. The information the Society provides should not be considered medical advice, nor is it intended to replace
consultation with a qualified physician. The Society does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Rosacea may vary substantially from one patient to another, and treatment must be tailored by a physician for each individual case. For more information, visit About Us.